retatrutide mechanism gip glp-1 glucagon triple agonist Demonstrated metabolic effects of GIP, and GCG agonism as mono, Retatrutide online: complete guide to
Description
GIP showed a diminished effect in boosting insulin secretion in T2D patients, for reasons that are still not understood
Common experiences during week 1-2 include slight changes in appetite patterns, mild nausea that differs from what tirzepatide caused (more constant and less meal-related), and subtle shifts in bowel habits
No clinical trial has evaluated retatrutide in women with PCOS, and no human efficacy or safety for a PCOS indication has been demonstrated
Lancet 403 , 16351648 (2024)
Vagal afferent dysfunction in obesity: cause or effect
Am J Hematol
